Bexsero (meningococcal group B Vaccine (rDNA, component, adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- meningococcal group B Vaccine (rDNA, component, adsorbed)
- Company
- GSK Vaccines S.r.l.
- Status
- Authorised
- Therapeutic area
- Meningitis, Meningococcal
- CHMP opinion
- Thu 15 Nov 2012
- EU approval
- Sun 13 Jan 2013
- Application
- EMEA/H/C/002333
- ATC
- J07AH09
- Official record
- www.ema.europa.eu
Indication
Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains.
Regulatory milestones
No milestones recorded in the last year.
Follow Bexsero
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.